ASH 2021: Dr. Constantine Tam on Zanubrutinib in Combination with Venetoclax for Patients with Deletion 17p
CLL and SLL patients with deletion 17p do not respond well to chemoimmunotherapy. But new targeted therapies may help. Zanubrutinib is a next-generation BTK inhibitor being tested in combination with venetoclax for treating patients with deletion 17p. Results from a Phase III trial of this combination were presented at the 2021 ASH meeting.